Tags

Type your tag names separated by a space and hit enter

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Abstract

The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95% confidence interval (CI): 1.37, 2.29), HR = 1.57 (95% CI: 1.14, 2.17), and HR = 1.40 (95% CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95% CI: 1.01, 1.46), HR = 1.20 (95% CI: 1.00, 1.45), and HR = 1.34 (95% CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95% CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. jschenk@fhcrc.org

    , , , , ,

    Source

    American journal of epidemiology 176:2 2012 Jul 15 pg 156-63

    MeSH

    Acetaminophen
    Aged
    Anti-Inflammatory Agents, Non-Steroidal
    Arthritis
    Aspirin
    Cohort Studies
    Comorbidity
    Headache
    Humans
    Incidence
    Male
    Middle Aged
    Models, Statistical
    Musculoskeletal Diseases
    Obesity
    Overweight
    Prospective Studies
    Prostatic Hyperplasia
    Prostatic Neoplasms
    Risk Factors
    Smoking

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    22759721

    Citation

    Schenk, Jeannette M., et al. "Indications for and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 176, no. 2, 2012, pp. 156-63.
    Schenk JM, Calip GS, Tangen CM, et al. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012;176(2):156-63.
    Schenk, J. M., Calip, G. S., Tangen, C. M., Goodman, P., Parsons, J. K., Thompson, I. M., & Kristal, A. R. (2012). Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology, 176(2), pp. 156-63. doi:10.1093/aje/kwr524.
    Schenk JM, et al. Indications for and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2012 Jul 15;176(2):156-63. PubMed PMID: 22759721.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. AU - Schenk,Jeannette M, AU - Calip,Gregory S, AU - Tangen,Catherine M, AU - Goodman,Phyllis, AU - Parsons,J Kellogg, AU - Thompson,Ian M, AU - Kristal,Alan R, Y1 - 2012/06/28/ PY - 2012/7/5/entrez PY - 2012/7/5/pubmed PY - 2012/9/18/medline SP - 156 EP - 63 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 176 IS - 2 N2 - The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men without BPH at baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 471) was defined as medical or surgical treatment or at least 2 International Prostate Symptom Score (I-PSS) values greater than or equal to 15. Proportional hazards models using time-dependent exposure for NSAID use were employed to estimate covariate-adjusted associations of NSAID-related medical conditions and NSAID use with BPH risk. Arthritis, other inflammation-related musculoskeletal conditions, and headaches were associated with increased BPH risk (hazard ratio (HR) = 1.77 (95% confidence interval (CI): 1.37, 2.29), HR = 1.57 (95% CI: 1.14, 2.17), and HR = 1.40 (95% CI: 1.09, 1.80), respectively). Use of any NSAID, use of aspirin, and use of nonaspirin NSAIDs were associated with significant increases in BPH risk (HR = 1.21 (95% CI: 1.01, 1.46), HR = 1.20 (95% CI: 1.00, 1.45), and HR = 1.34 (95% CI: 1.07, 1.69), respectively). Control for indications for NSAID use, including baseline I-PSS, attenuated the associations slightly, but all became nonsignificant. Among men with no indications for NSAID use, the hazard ratio for any NSAID use was 1.06 (95% CI: 0.82, 1.38). The modest associations of NSAID use with BPH risk in this cohort were probably due to confounding by indication, and NSAID use was not associated with BPH risk. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/22759721/Indications_for_and_use_of_nonsteroidal_antiinflammatory_drugs_and_the_risk_of_incident_symptomatic_benign_prostatic_hyperplasia:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwr524 DB - PRIME DP - Unbound Medicine ER -